Morningstar

Eli Lilly Buys Engage Biologics for Up to $202 Million

Provided by Dow Jones

By Elias Schisgall 




  Eli Lilly has acquired Engage Biologics, a preclinical biotechnology company developing a novel DNA delivery system, for up to $202 million in cash. 



  The pharmaceutical company's financing for the acquisition includes an upfront payment, as well as subsequent payments based on development milestones, Engage said Wednesday. 



  Engage's DNA delivery system being developed to overcome potency, tolerability, and redosability obstacles in existing DNA delivery methods, the company said. 



  "We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine," Engage Chief Executive Will Olsen said. "We believe that the combination of Engage's platform with Lilly's significant capabilities will meaningfully accelerate development of new genetic therapies." 



  The purchase of Engage adds to a string of acquisitions by Lilly this year. The company's recent purchases include multibillion-dollar acquisitions of Ajax Therapeutics, Kelonia Therapeutics, Centessa Pharmaceuticals and Orna Therapeutics. 





  Write to Elias Schisgall at elias.schisgall@wsj.com 





  (END) Dow Jones Newswires



  May 20, 2026 10:24 ET (14:24 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for November
 
Plus, whether Microsoft, Alphabet, or Amphenol look attractive after earnings.  
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
This Once-Hot AI Stock Now Looks Deeply Undervalued
 
This chip stock looks cheap at a 30% discount, and its biggest growth years could still be ahead. 
 
 
William Kerwin, CFA 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
Tech Stocks Sell Off as Intel, Amazon Earnings Spook Investors
 
Underwhelming results have added to investor worries about AI spending. 
 
 
Vicky McKeever 
 
 
 
He Tried Shorting Jim Cramer’s Stock Picks. It Cost Him More Than Money
 
Historian Joseph Moore explores why a promising product can fail as an investment and why beating the market may not be worth the effort. 
 
 
Christine Benz and Amy C. Arnott, CFA 
 
 
 
 

			Sponsor Center